- Clinical Trials
- January 2024
- 60 Pages
Global
From €1192EUR$1,250USD£1,016GBP
- Report
- May 2024
- 134 Pages
Global
From €6196EUR$6,499USD£5,281GBP
- Report
- June 2024
- 898 Pages
Global
From €5339EUR$5,600USD£4,551GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1192EUR$1,250USD£1,016GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1192EUR$1,250USD£1,016GBP
- Clinical Trials
- January 2024
- 100 Pages
Global
From €1907EUR$2,000USD£1,625GBP
- Report
- May 2019
- 84 Pages
Global
From €6669EUR$6,995USD£5,684GBP
- Drug Pipelines
- June 2018
- 43 Pages
Global
From €3337EUR$3,500USD£2,844GBP
- Report
- October 2023
- 78 Pages
Global
From €3500EUR$3,933USD£3,088GBP
- Report
- December 2022
- 42 Pages
Global
From €3337EUR$3,500USD£2,844GBP
- Report
- October 2022
- 57 Pages
Global
From €3337EUR$3,500USD£2,844GBP
- Report
- October 2022
- 69 Pages
Global
From €3337EUR$3,500USD£2,844GBP
- Report
- October 2022
- 41 Pages
Global
From €3337EUR$3,500USD£2,844GBP
- Report
- May 2022
- 36 Pages
Global
From €3337EUR$3,500USD£2,844GBP
- Report
- May 2022
- 32 Pages
Global
From €3337EUR$3,500USD£2,844GBP
- Drug Pipelines
- March 2019
- 44 Pages
Global
From €3337EUR$3,500USD£2,844GBP
- Drug Pipelines
- August 2018
- 78 Pages
Global
From €3337EUR$3,500USD£2,844GBP
- Drug Pipelines
- August 2018
- 55 Pages
Global
From €3337EUR$3,500USD£2,844GBP
- Drug Pipelines
- August 2018
- 50 Pages
Global
From €3337EUR$3,500USD£2,844GBP
- Drug Pipelines
- June 2018
- 35 Pages
Global
From €3337EUR$3,500USD£2,844GBP
The Metabotropic Glutamate Receptor (mGluR) market is a subset of the Central Nervous System (CNS) drugs market. mGluRs are a class of G-protein coupled receptors that are involved in a variety of physiological processes, including learning and memory, pain perception, and anxiety. mGluRs are also implicated in a number of neurological disorders, such as Alzheimer's disease, Parkinson's disease, and schizophrenia. As such, mGluR-targeted drugs are being developed to treat these conditions.
The mGluR market is highly competitive, with a number of large pharmaceutical companies and biotechnology firms developing mGluR-targeted drugs. Companies such as Merck, Pfizer, Novartis, and Eli Lilly are actively researching and developing mGluR-targeted drugs. Additionally, a number of smaller biotechnology firms, such as Neurocrine Biosciences, ACADIA Pharmaceuticals, and Ovid Therapeutics, are also developing mGluR-targeted drugs. Show Less Read more